Goldman Sachs Group reiterated their buy rating on shares of Takeda Pharmaceutical (NYSE:TAK) in a research report report published on Tuesday morning, The Fly reports.
Separately, Zacks Investment Research upgraded shares of Takeda Pharmaceutical from a hold rating to a buy rating and set a $23.00 price target on the stock in a research note on Wednesday, March 13th.
TAK opened at $20.94 on Tuesday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 2.81 and a current ratio of 3.06. The stock has a market capitalization of $33.48 billion, a price-to-earnings ratio of 19.57, a P/E/G ratio of 5.87 and a beta of 0.73. Takeda Pharmaceutical has a twelve month low of $15.50 and a twelve month high of $26.95.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Featured Article: What is a Call Option?
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.